News & Events

Purespring Therapeutics to Present at Piper Sandler’s 37th Annual Healthcare Conference

London – 25 November 2025 Purespring Therapeutics, a precision nephrology company leading the development of…

Purespring to present three posters at the American Society of Nephrology Kidney Week 2025

New information to be presented on the study design and methodology of Purespring’s Phase I/II…

Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

Members of the Purespring management team will present at Chardan’s 9th Annual Genetic Medicines Conference.…

Purespring Therapeutics to Participate in the 2025 BofA Healthcare Trailblazers Private Company Conference

Members of the Purespring management team will participate in the 2025 Bank of America Healthcare…

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK…

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver…

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)

EMA designation provides orphan status to medicines being developed for rare conditions that are intended…

Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving…

Purespring Therapeutics presents new preclinical data on novel gene therapy for IgA Nephropathy at ASN Kidney Week 2024

Results from the study underpin the potential of Purespring’s lead AAV gene therapy programme, PS-002,…

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases

Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital…

Q&A with Alice Brown

July 2024 Can you tell us a bit about yourself and your background and what…

Purespring Therapeutics presents preclinical data at the 61st ERA Congress

Data establishes the potential of AAV gene therapy to deliver transgenes to the podocyte to…

Q&A with Fredrik Erlandsson

March 2024 When and how did you first get involved with Purespring? Purespring caught my…

Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer

Appointments of Fredrik and Peter complete build-out of senior team. London— 6 September 2023 Purespring…

Purespring Therapeutics appoints Sachin Kelkar as CFO following appointment of Julian Hanak as CEO

Senior leadership team strengthened as Purespring prepares kidney gene therapy programmes for clinical development. London—…

World Kidney Day 2023: Transforming Kidney Disease through Podocyte Gene Therapy

World Kidney Day 2023: Transforming Kidney Disease through Podocyte Gene Therapy Authors: Pille Harrison, Moin…

Purespring Therapeutics to Participate in Upcoming Q4 Conferences

Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases,…

Purespring Therapeutics strengthens scientific leadership with the appointment of Alice Brown as Chief Scientific Officer